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Immunotherapy involving checkpoint blockades of inhibitory co-receptors is effective in
combating cancer. Despite this, the full range of mediators that inhibit T-cell activation and
influence anti-tumor immunity is unclear. Here, we identify the GTPase-activating protein
(GAP) Rasal1 as a novel TCR-ZAP-70 binding protein that negatively regulates T-cell acti-
vation and tumor immunity. Rasal1 inhibits via two pathways, the binding and inhibition of the
kinase domain of ZAP-70, and GAP inhibition of the p21ras-ERK pathway. It is expressed in
activated CD4 + and CD8+ T-cells, and inhibits CD4+ T-cell responses to antigenic pep-
tides presented by dendritic cells as well as CD4+ T-cell responses to peptide antigens
in vivo. Furthermore, siRNA reduction of Rasal1 expression in T-cells shrinks B16 melanoma
and EL-4 lymphoma tumors, concurrent with an increase in CD8+ tumor-infiltrating T-cells
expressing granzyme B and interferon γ-1. Our findings identify ZAP-70-associated Rasal1 as
a new negative regulator of T-cell activation and tumor immunity.
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The advent of immunotherapy has ushered in a new era oftherapies for cancer1. Present approaches involve the use ofimmune checkpoint blockade against programmed cell
death 1 (PD-1) and other inhibitory receptors (IRs) to enhance T-
cell responses2,3. An alternate approach is to directly target
negative signaling pathways that limit T-cell responses to neo-
antigens in tumors. T-cell activation is mediated by protein
kinases p56lck and zeta chain-associated protein kinase 70 (ZAP-
70)4,5. CD4 and CD8 bind to p56lck 6–8 where the kinase phos-
phorylates various substrates that include immunoreceptor
tyrosine-based activation motifs (ITAMs) on the zeta and CD3
chains of the T-cell receptor (TCR)9 for the recruitment of the
second kinase, ZAP-7010. Ligation of the TCR complex, in turn,
induces a tyrosine phosphorylation cascade involving various
enzymes and adaptor proteins such as linker for the activation of
T cells (LAT)5,11. The adaptor complex, LAT-SLP-76 regulates
calcium mobilization11–13, while the adaptor SKAP1 (aka SKAP-
55) acts a scaffold for the activation of LFA-114–16 via the reg-
ulation of RapL–Rap1 complex formation17,18. SKAP1 also binds
to the Polo-like kinase 1 (PLK1) for the optimal cell cycling of
T cells19 and the p21 activating exchange factor RasGRP117,20.
The outcome of the activation process also involves inhibitory
co-receptors and negative intracellular mediators that prevent
excess inflammation and safeguard against the development of
autoimmunity. Key among these are programmed cell death
protein-1 (PD-1), T-cell immunoreceptor with Ig and ITIM
domains (TIGIT), and others which possess immunoreceptor
tyrosine-based inhibition motifs (ITIMs) or immunoreceptor
tyrosine-based switch motifs (ITSMs) that bind the phosphatases
Src homology region 2 domain-containing phosphatases 1 and 2
(SHP-1 and SHP-2). In the case of PD-1, negative signaling has
been attributed to SHP-2 binding to the ITSM2,21,22, where it
inhibits the phosphoinositide 3-kinase (PI 3 K)-protein kinase B
(PKB) (also AKT) pathway leading to altered metabolism and a
block in cell cycle progression23. Other negative regulators
include the E3 ligases of the ubiquitin pathway24–26.
The TCR complex also stimulates the small GTPase p21ras that
operates upstream of the Ras–Raf–mitogen-activated protein
kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)
signaling pathway27. p21ras is active when bound to GTP, and
inactive in a GDP form. Guanine nucleotide exchange factor
(RasGEF) RasGRP1 and Son of Sevenless (SOS) stimulate the
release of GDP in exchange for GTP. GRB-2-associated SOS
binds the YMNM motif of CD2828,29 and the LAT complex30.
Conversely, GTPase-activating proteins (RasGAPs) inhibit p21ras
by promoting conversion of active GTP-bound Ras to the inactive
GDP-bound form31. The inactivation of the p21ras-ERK pathways
has been linked to the induction of T-cell nonresponsiveness or
anergy32,33.
The Ras protein activator-like 1 protein (Rasal1) is a member
of a GAP family that includes p120 RasGAP (or Rasa1), NF134,35,
and Rasa2-436–38. Each contains two N-terminal C2 domains
which is followed by a GAP domain, a PH domain, and a Bruton
tyrosine kinase (BTK) motif39. The PH domain of Rasa2 and
Rasa3 mediates membrane recruitment, while the Rasal1 C2
domain senses levels of intracellular calcium36. By sensing oscil-
lations in intracellular calcium, Rasal1 shuttles between the
membrane and cytoplasm. Translocation to the membranes is
driven via the C2 domain binding the membrane phospholipids.
In addition to p21ras, Rasal1 shows GAP activity toward the Ras-
related small GTPase, Rap40. Purified Rasal1 alone is devoid of
RasGAP activity since it requires a change in GAP domain
confirmation as triggered by membrane localization. The
calcium-dependent C2 domain interaction with membrane
phosphatidylserine and phosphatidylinositol lipids is the critical
event that triggers its RasGAP activity41.
Altered or mutated Rasal1 has also been linked to various
cancers42–44, where it serves as a tumor suppressor in human
thyroid45, colon44, liver46, and thyroid cancers47.
Despite its importance in the transformation of cells, the role of
Rasal1 in T-cell activation and cancer immunotherapy has yet to
be explored. Here, we have shown by a combination of tandem
affinity chromatography, co-precipitation, and proximity ligation
analysis (PLA) that Rasal1 binds to the kinase domain of ZAP-70
of the TCR complex and inhibits anti-CD3 activation of ERKs in
T cells. It regulates in vitro and in vivo T-cell responses to peptide
antigen. Further, the knockdown of Rasal1 in T-cells limits B16
melanoma pulmonary metastasis and the growth of solid EL-4
lymphoma tumors. This enhanced anti-tumor effect is accom-
panied by a marked increase in CD8+ tumor-infiltrating T-cells
(TILs) expressing killer effector molecules granzyme B (GZMB)
and interferon γ-1 (IFNγ1). Overall, our findings identify a novel
TCR-associated protein that appears after T-cell activation and
negatively regulates T-cell activation and antitumor immunity.
Results
Rasal1 is a TCR-associated GAP in T cells. TCR zeta tandem
affinity purification (TAP) and mass spectrometry (MS) were
used to identify novel TCR/CD3 interaction partners in recon-
stituted TCR-null zeta−/− 3A9 cells48,49. The TCR-null zeta−/−
3A9 cell is a murine T-cell hybridoma which was reconstituted
with expression of a zeta chain coupled to Strep-II and His/V5
tags (i.e., HIS-STREP-II-tagged zeta) for purification (Supple-
mentary Fig. 1). The sequential two-step purification approach
using Strep-II and V5/His tags minimizes the presence of non-
specific contaminating material. While TCR-null zeta−/− 3A9
cells do not express the surface forms of the TCR, expression of
the zeta chain by transfection with our TAP-zeta constructs
restored TCR expression (Supplementary Fig. 1). Reconstituted
clones with levels of TCR surface expression comparable to
peripheral T cells (i.e., Clone 1.2) (lower panel) were selected.
Clone 1.2 was sorted by FACS and grown to establish a cell line.
The hybridoma clone was then activated for 5 min with soluble
anti-CD3 prior to two-step TAP sequential chromatography to
co-purify associated proteins for analysis by SDS-PAGE and sil-
ver staining, as well as tandem mass spectrometry (MS/MS).
From this, MS/MS identified peptides for the T-cell receptor
alpha, beta, gamma chains, and CD3 and zeta subunits (Fig. 1a,
right panel). Under the same conditions, four peptides corre-
sponding to a Ras GTPase-activating like 1 (Rasal1) were detected
in each experiment (n= 3) (Supplementary Fig. 2). A TCR-
specific protein at 90–95 KD, the Mr for Rasal1 was also seen by
silver staining of SDS-PAGE (left panel). For technical reasons
involving the need to cut the gel for MS/MS analysis, a gel slice in
the region of 70 kDa was excluded, and hence, ZAP-70 peptides
were not seen by MS/MS. However, confirmation of the presence
of ZAP-70 in our 3A9 cells was seen by anti-CD3 precipitation
followed by anti-ZAP-70 blotting (Fig. 1b, lanes 1 and 2). Fur-
thermore, the level of co-precipitated ZAP-70 increased following
anti-CD3 stimulation for 10 min (lane 2 vs 1). Overall, using TAP
analysis, these studies showed that Rasal1 associates with the
TCR–CD3 complex in T cells.
To assess Rasal1 expression in T cells, murine naive CD4 and
CD8+ T cells were ligated with anti-CD3 antibodies followed by
a measure of mRNA levels for Rasal1 and related Rasal3 (Fig. 1c).
CD4+ T cells showed upregulation of both Rasal1 and 3 by 24 h
followed by a reduction in their expression at 48 h. By contrast,
CD8+ T cells showed a sustained increase in the expression of
Rasal1 at 24 and 48 h, while Rasal3 did not increase with
stimulation. Overall, these data showed that Rasal1 is expressed in
CD4 and CD8+ activated T cells in response to TCR ligation.
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In addition, we found that anti-CD3 induced the translocation
of Rasal1 from cytosol to the membranes of activated T cells
(Fig. 1d). Mouse primary T cells were pre-activated with anti-
CD3 for 36 h to induce Rasal1 expression, followed by a rest for
24 h and re-ligated with soluble anti-CD3 for various times. Anti-
CD3 ligation resulted in the presence of Rasal1 in the membranes
for 5–15 mins followed by a decrease at 30 min. As a control, the
transmembrane protein, LAT was only found in the membrane
fraction with no cross-contamination seen in cytosolic fractions.
These data showed that Rasal1 can be induced to associate with
the membranes of T cells by anti-CD3 ligation.
To assess the proximity of Rasal1 with the TCR, we also carried
out a nearest neighbor examination of proteins using proximity
ligation analysis (PLA) (Fig. 2a). Antibodies to ZAP-70 and Rasal1
were employed together with isotype-specific antibodies with the
Duolink-TM detection system in Jurkat T cells50,51. Anti-Rasal1
and anti-ZAP-70 showed a strong positive signal in response to
anti-CD3 ligation, while no signal could be detected in resting cells.
DAPI was used to stain the nucleus of cells (see blue). While PLA
can show nearest neighbor localization, it cannot be used accurately
to determine the intracellular localization of the complexes. These
data provided evidence that anti-CD3 can induce close proximity
between Rasal1 and ZAP-70 in activated T cells.
Furthermore, biochemically, anti-Rasal1 co-precipitated ZAP-
70 from primary murine T cells that had been pre-activated to
induce Rasal1 followed by a rest for 12 h and then anti-CD3
ligation for 5 min (Fig. 2b). Anti-Rasal1 co-precipitated ZAP-70
from these primary cells ligated with anti-CD3 (lane 4). Little, if
any co-precipitated, ZAP-70 was seen in resting cells (lane 3).
Similarly, anti-Rasal1 co-precipitated ZAP-70 upon anti-CD3
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Fig. 1 TCR complex purification and Rasal1 association with ZAP-70 in the TCR complex. a Analytic gel from tandem affinity purification (TAP) of TCR plus
associated proteins captured from TCR-constituted cells (TCR complex) versus TCR-null negative control cells (control) (left panel). Chart showing the list
of TCR-associated proteins identified by MS analysis (right upper panel). The structure of Rasal1 (right lower panel). b Co-precipitation of ZAP-70 with
TCR from 3A9 T cells. 3A9 cells were stimulated for 10 min with anti-CD3 followed by immunoprecipitation with anti-TCR zeta and blotting with anti-ZAP-
70 or anti-zeta. Lane 1: resting T cells; lane 2: anti-CD3-stimulated T cells. c Rasal1 expression is induced with anti-CD3 activation. Relative fold change
expression of Rasal1 versus Rasal3 upon anti-CD3 stimulation of CD4+ and CD8+ peripheral T cells. 18 s rRNA served as a control. d Anti-CD3 induces
Rasal1 translocation to the membranes of T cells. Stimulation-dependent association of Rasal1 with the membrane (upper panel) versus cytosolic Rasal1
(lower panel). Anti-actin served as a loading control. LAT was used as a marker of membrane enrichment fractionation (n= 3)
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Fig. 2 Rasal1 binds to the immune cell tyrosine kinase ZAP-70.
a Proximity ligation assay (PLA) of Rasal1 and ZAP-70 in Jurkat T-cells
stained with DAPI, anti-Rasal1, and anti-ZAP-70. Positive PLA signal
(fluorescent dots) indicates a distance of 30–40 nm between Rasal1 and
ZAP-70 in anti-CD3-activated T cells, indicating their close proximity
(n= 2). b Anti-Rasal1 co-precipitates ZAP-70 from primary mouse
T cells. Lane 1–2 loading controls, lanes 3-4: anti-Rasal1 IP: lanes 2 and 4.
Cells were stimulated with anti-CD3 ligation for 5 min vs IgG control
ligation in lanes 1 and 3. c Anti-Rasal1 co-precipitates ZAP-70 from
transfected Jurkat T cells. Lanes 1: nonligated (i.e., IgG); lane 2: anti-CD3
ligated T cells for 5 min. Lower panel shows similar level of ZAP-70
expression in lysates of (n= 2)
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ligation of human Jurkat T cells (Fig. 2c, lane 2). Overall, the
combined use of TAP, PLA, and co-precipitation analysis showed
that a portion of Rasal1 associates with the ZAP-70 and is
recruited to the TCR upon activation.
Rasal1 binds to the kinase domain of ZAP-70. In order to assess
the site of binding between Rasal1 and ZAP-70, various deletion
mutants of ZAP-70 were cloned and expressed for binding studies
(Fig. 3a). These deletion mutants included the N-SH2 domain
with the intervening I-A region, the N- and C-SH2 domains with
the intervening I-A region, the N- and C-SH2 domains with the
intervening I-A and I-B region, and the isolated kinase domain
(left panel). The PCR products for the ZAP-70 fragments are also
shown (right panel). Each protein was then expressed in
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Fig. 3 Rasal1 binds to the kinase domain of ZAP-70 and inhibits ZAP-70 kinase activity. a Deletion mutants of ZAP-70 that include the V5-tagged N-
terminal SH2 domain plus the intervening region, the N-terminal SH2 domain plus the intervening region and the C-terminal-oriented SH2 domain, the N-
terminal SH2 domain plus the intervening region and the C-terminal-oriented SH2 domain plus the intervening I-B region and the kinase domain of ZAP-70.
Right panel: PCR of ZAP-70 fragments. b The Rasal1 binds to the kinase domain of ZAP-70. Each of the proteins were expressed in 293T cells in the
presence of Flag-tagged Rasal1 (left panel). Anti-Rasal1 precipitation resulted in the co-precipitation of full-length ZAP-70 and the kinase domain of ZAP-
70 (right panel) (n= 2). c Rasal1 inhibits the kinase activity of ZAP-70 and the phosphorylation of LAT. Recombinant active ZAP-70 from baculovirus was
incubated with Flag-LAT from 293T cells as a substrate in the presence of increasing concentrations of GST-Rasal1 and γ-32P ATP for 30min at 37 °C.
Increasing concentrations of GST-Rasal1 inhibited ZAP-70 autophosphorylation and the phosphorylation of LAT (lanes 3–6). Lower panels: input levels of
GST-ZAP-70 and LAT were assessed by western blotting (n= 2). d Rasal1 inhibits the kinase activity of ZAP-70 and the phosphorylation of LAT.
Recombinant active ZAP-70 from baculovirus was incubated with Flag-LAT from 293T cells as a substrate in the presence of increasing concentrations of
GST-Rasal1 and cold ATP for 30min at 37 °C. Increasing concentrations of GST-Rasal1 inhibited ZAP-70 autophosphorylation and the phosphorylation of
LAT (n= 2). Lower panels show blots for Flag-LAT and GST-Rasal1 expression. e Rasal1, but not Bora, inhibits the kinase activity of ZAP-70 and the
phosphorylation of LAT. Recombinant active ZAP-70 from baculovirus was incubated with GST-Bora or GST-Rasal1 with γ-32P ATP for 30min at 37 °C.
Increasing concentrations of GST-Rasal1, but not GST-Bora, inhibited ZAP-70 autophosphorylation. GST-Bora (lanes 2–5); GST-Rasal1 (lanes 6–9). f LAT
phosphorylation of Y-171 is reduced in the presence of Rasal1 in Jurkat T-cells. Jurkat cells were transfected with Rasal1 and ligated for 5 min with anti-CD3.
Rasal1 transfection (lanes 3, 4); resting (anti-IgG) (lanes 1, 3); anti-CD3 (lanes 3, 4) (n= 3). Right panel: histogram showing the quantification of phospho-
LAT normalized to total LAT levels in the blot
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293T cells in the presence of Flag-tagged Rasal1 (Fig. 3b). Intri-
guingly, anti-Rasal1 co-precipitated only full-length ZAP-70 or
the kinase domain of ZAP-70. These results indicated that Rasal1
bound to the kinase domain of ZAP-70.
To assess the implications of binding, we then measured the
kinase activity of GST-ZAP-70 in the presence and absence of
GST-purified Rasal1 (Fig. 3c–f). We first assessed ZAP-70
autophosphorylation and the phosphorylation of LAT, an
established substrate of ZAP-7052. Assays were run using
radioactive ATP (i.e., hot assay) (Fig. 3c), or as a cold kinase
assay (Fig. 3d). Recombinant active ZAP-70 isolated from
baculovirus was incubated with Flag-LAT from 293T cells, as a
substrate, in the presence of increasing amounts of GST-Rasal1
for 30 min at 37 °C. In the case of the radioactive assay using γ-
32P ATP, GST-ZAP-70 alone showed the presence of an
autophosphorylation band at 76 KD (Fig. 3c, upper panel, lane
1). The addition of LAT resulted in the labeling of LAT at 40 KD
(lane 2), while the titration of increasing amounts of Rasal1
inhibited both autophosphorylation and LAT labeling (lanes
3–6). Commassie staining revealed the presence of exogenously
added GST-Rasal1, while immunoblotting confirmed the pre-
sence of equal levels of GST-ZAP-70 and Flag-LAT (lower
panels).
Similarly, in the presence of cold ATP, immunoblotting with
anti-phospho-tyrosine identified a GST-ZAP-70 band (Fig. 3d,
upper panel, lane 1), while the addition of Flag-LAT showed the
presence of the phosphorylated LAT at tyrosine 171 (Y-171) (lane
2). By contrast, the addition of increasing amounts of GST-Rasal1
markedly diminished the autophosphorylation of ZAP-70 and the
presence of phospho-Y-171 of anti-Flag LAT precipitates (lanes
3–6). Anti-LAT confirmed the presence of equal amounts of LAT,
while Rasal1 blotting confirmed the increasing amounts of GST-
Rasal1 added to the assay (lower panel). GST-Bora (protein
aurora borealis), with the same MW as Rasal1, was also used as a
control (Fig. 3e). However, the addition of increasing amounts of
GST-Bora had no effect on the autophosphorylation of ZAP-70 in
a radioactive kinase assay (lanes 1–5). This contrasted with the
inhibitory effect of GST-Rasal1 on ZAP-70 autophosphorylation
(lanes 6–9). Commassie staining confirmed the presence of
exogenously added GST-Bora and GST-Rasal1, while immuno-
blotting confirmed the presence of equal levels of GST-ZAP-70
(lower panels).
Lastly, we monitored the phosphorylation of the adaptor LAT
at Y-171 in Jurkat T cells (Fig. 3f). Jurkat cells were transfected
with mock vector (i.e., SRalpha) or Flag-Rasal1 prior to ligation
with anti-CD3 and immunoblotting. Anti-CD3 induced the
phosphorylation of LAT of Y-171, as previously reported10,51.
The co-expression of Flag-Rasal1 reduced the phosphorylation of
LAT consistent with the notion that Rasal1 inhibits ZAP-70. The
normalization of the p-LAT Y171 signal relative to the expression
of LAT confirmed that the phosphorylation of LAT at Y-171 was
reduced by ~50% (histogram, lower panel). Overall, these data
showed that Rasal1 can bind to the kinase domain of ZAP-70,
and in the process, inhibit its catalytic activity.
Rasal1 inhibits ERK activation in T cells. On another level,
Rasal1 is also a member of RasGAP family that includes p120
RasGAP and NF1 which inactivate p21ras 34,35. p21ras in turn
operates upstream of extracellular-activated kinase (ERK) of the
Ras–Raf-MEK-ERK pathway53. To investigate this pathway, pri-
mary mouse T cells were transfected with Flag-Rasal1, and ligated
with anti-CD3 for 5 min followed by blotting against phospho-
activation sites Thr202/Tyr204 on ERK (Fig. 4a). Levels of acti-
ve ERK1,2 were measured by phosphorylation at residues
Thr202/Tyr20454. While anti-CD3 induced strong pERK1,2
phosphorylation, the expression of transfected Rasal1 inhibited
this activation as seen in examples of two representative experi-
ments (upper and lower panels).
Flow cytometry also showed that Rasal1-HA reduced pERK1,2
when gated on CD3+ Rasal1-HA+ cells over a time course of
15 min (Fig. 4b, upper panel). Levels of pERK1/2 increased until
10 min followed by a decline at 15 min. By contrast, the
transfection and expression of HA-Rasal1 markedly inhibited
(>90%) ERK activation at all times. As a control, anti-CD3
induced p38 activation as detected by phospho-p38 MAPK
(Thr180/Tyr182) antibody was unaffected by the expression of
Rasal1-HA (lower panel).
The phosphorylation of proximal activators of ERK, Raf, and
MEK-1 on phospho-activation sites Raf-Ser338 and MEK-Thr286
were also examined (Fig. 4c). In both cases, anti-CD3 was seen to
increase phosphorylation in mock transfected cells (lane 2 vs 1).
By contrast, the transfection with Flag-Rasal1 reduced the
phosphorylation of both mediators (lane 4 vs 2). Collectively,
these data showed that Rasal1 inhibits anti-CD3-induced p21ras-
ERK activation in T cells.
Rasal1 inhibits T-cell activation. Given these results, we next
assessed the role of Rasal1 in regulating T-cell activation. For this,
primary mouse T cells from DO11.10/Rag2−/− TCR transgenic
mice were transfected with Flag-tagged Rasal1 (Fig. 5a). SRalpha
(i.e., mock) and Rasal1- transfected cells were then activated
in vitro by bone marrow-derived dendritic cells (BMDCs)
exposed to ovalbumin (OVA) peptide antigen followed by an
examination of proliferation on day 4. BMDCs were isolated and
generated as described17,55. Rasal1 expression reduced prolifera-
tion by 50–60% at 5 µg and 10 µg OVA as monitored by 3H-
thymidine incorporation. CTLA-4 Ig served as a control to block
the response. Blotting confirmed the expression of Rasal1 (upper
inset). Likewise, a titration of anti-CD3 showed that Rasal1
inhibited proliferation as monitored by 3H-thymidine incor-
poration (Fig. 5b). Inhibition was seen less evident at lower anti-
CD3 concentrations of 0.1–0.5 µg/ml, but pronounced at 80–90%
relative to vector control when higher concentrations of anti-CD3
from 1.0–6.0 µg/ml were used to stimulate cells. This finding
suggests that Rasal1 regulation of T-cell proliferation is affected
by the strength of the TCR signal. Furthermore, inhibition at 2
µg/ml was seen at both 48 and 72 h post-anti-CD3 ligation (upper
inset). Similarly, expression of Rasal1 inhibited the anti-CD3
increase in NFAT-AP2 IL-2 promoter activity when co-
transfected into Jurkat T cells (Fig. 5c). By contrast, esiRNA
(enhanced siRNA) knockdown (KD) of endogenous Rasal1
potentiated the proliferation of primary T cells (Fig. 5d). Blotting
with anti-Rasal1 confirmed the reduction in Rasal1 expression
(right upper panel).
As an additional control, the contact time between T cells and
dendritic cells (DCs) was measured using live cell imaging
(Fig. 5e). Rasal1 transfection had no effect on contact times unlike
in the case of immune cells adaptors, such as ADAP and
SKAP115,17. These data showed that Rasal1 negatively regulates
the proliferation of T cells without affecting the contact times
between T cells and presented antigen-presenting cells.
Rasal1 modulates in vivo responses to antigen. We next
assessed whether Rasal1 could affect in vivo proliferation
(Fig. 6). For this, DO11.10 T-cells transfected with scrambled or
Rasal1 siRNAs were adoptively transferred into Balb/c mice
followed by injection with 50ug OVA257-264 peptide 24 h later.
T cells from lymph nodes were isolated on day 5, and assessed
for numbers of cells and activation markers (Fig. 6a). Flow
cytometry confirmed the reduction in Rasal1 expression
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resultant from Rasal1 siRNA transfection (Fig. 6b). We
observed an increase in lymph node (LN) size or volume from a
mean of 10.2 to 13.7 mm3 in mice with adoptively trans-
ferred Rasal1 siRNA KD cells relative to transferred cells
expressing scrambled siRNA (Fig. 6c). Further, the percent of
DO11.10 T cells increased from 20% in control to 70% in Rasal1
KD cells (Fig. 6d). DO11.10 T cells were identified using an
anti-mouse TCR DO11.10 antibody (BioLegend)56. Among
these cells, there was an increase in the percent of cells
expressing the activation marker Ki-67 (Fig. 6e). We also
observed an increased expression of CD25 and CD69 in Rasal1
KD cells (Fig. 6f). No significant change was seen in the
expression of differentiation marker CD62L. Although attempts
were made to label cells with CFSE, the in vivo detection of dye
was poor (data not shown). These data show that the down-
regulation of Rasal1 can increase the proliferation and cell
expansion capacity of antigen-specific T cells in vivo.
Rasal1 siRNA in T cells reduces tumor growth. We next
assessed whether Rasal1 represented a potential therapeutic target
in anti-tumor immunity. To examine pulmonary metastasis,
B16F10 melanoma cells pulsed with OVA peptide were injected
intravenously (i.v.) into C57/BL/6 mice, as we have previously
described57,58. This was followed by the adoptive cell transfer of
purified OT-1 CD8+ T cells into mice (Fig. 7a, upper panel).
T cells had been transfected ex vivo 24 h earlier with scrambled
(SC) or Rasal1 siRNA. Lungs were harvested on day 14, and
pulmonary metastasis was monitored by counting tumor foci
(n= 4). Consistent with their recognition of OVA peptide, OT-1
T cells expressing scrambled siRNA reduced the number of foci
on lungs when compared with control mice that had been
injected with PBS alone (lower left panel and right histogram).
However, T cells expressing siRNA for Rasal1 significantly
reduced the number of B16 foci relative to the action of scram-
bled OT-1 cells. These data indicated that a reduction in Rasal1
expression enhanced the ability of adoptively transferred T cells
to limit the growth of B16 tumors.
We next examined the nature of the tumor-infiltrating
lymphocytes (TILs) isolated from the melanoma tumors (Fig. 7b).
From this, we observed a major increase in the numbers of CD8
+ T cells expressing Rasal1 siRNA relative to CD8+ T cells
expressing scrambled siRNA (see left histograms). When
averaged over several experiments and expressed as a percentage
of the TILs, we observed an increase in CD8+ T cells within the
TIL population from 12 to 33% (upper right panel) (n= 4).
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Furthermore, in another experiment which compared CD4 and
CD8 cells, we did not observe a change in the percentage of
infiltrating CD4+ cells (lower right panel). These data indicated
that the enhanced regression of the B16 tumors with reduced
Rasal1 expression was accompanied by an increase in the
presence of CD8+ TILs.
Furthermore, TILs from tumors of mice injected with T cells
expressing Rasal1 siRNA showed a significant increase in the
presence of CD8+ cells expressing granzyme B (GZMB) and
IFNγ1, the effector molecules of the CD8+ cytotoxic T cells
(Fig. 7c, left panels). The percentage of CD8+ cells expressing IL-
2 and TNFα showed upward trend, which was not statistically
significant (right panels). Overall, using adoptive cell therapy, we
found that Rasal1 KD promoted an increase in the presence of
CD8+ TILs in tumors with an increased expression of GZMB
and IFNγ1 which was accompanied by reduced pulmonary
metastasis of B16 tumors in mice.
We next assessed responses to a second tumor model, the EL-4
T-cell solid lymphoma model. Priming of OT-1 OVA-specific
T cells with SIINFEKL peptide of OVA (OVA257-264) produces a
specific cytolytic T-cell (CTL) response against tumor targets59.
EL4 cells were pre-treated with 2 µg of OVA peptide and washed
prior to injection. Tumors were allowed to grow until day 5
followed by injection of scrambled or Rasal1 siRNA expressing
cells (2 × 105) for 10–12 days (Fig. 8a). Tumor weight was
reduced from a mean of 580 to 370 mg in mice with Rasal1 KD
T cells relative to scrambled RNAi. Furthermore, there was a
fourfold increase in percent of TILs expressing CD8+ in the
tumors of mice injected with Rasal1 KD T cells relative to
scrambled RNAi (i.e., 8 vs 38% of CD8+ TILs) (Fig. 8b). By
contrast, no change in the percent of CD8+ T-cells was observed
in the spleens of mice (right panel). Furthermore, we observed an
increase in the percentage of CD8+ T-cells expressing the activa-
tion markers CD25 and CD69 in the TIL population in mice
injected with Rasal1 KD relative to scrambled RNAi expres-
sing T cells (Fig. 8c). By contrast, the expression of CD62L or
CD44 in TILs was unaffected by Rasal1 KD (Fig. 8d). Similarly,
an increase in the percentage of CD8+ TILs expressing GZMB
IL-2, and IFNγ1 was seen (Supplementary Fig. 3). Overall, Rasal1
KD promoted the expansion of CD8+ TILs in EL-4 tumors with
an increased expression of activation markers, accompanied by
the reduced growth of solid tumors in mice.
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Discussion
Present immunotherapy against cancer involves the use of
immune checkpoint blockade against PD-1 and other IRs to
enhance T-cell responses2,3. However, the discovery of new
receptors and intracellular signaling pathways is needed for more
effective cancer immunotherapy. Here, we identify a novel path-
way involving Rasal1, which associates with the T-cell receptor
following T-cell activation and which negatively regulates the
p21ras-ERK pathway in T cells. Rasal1 negatively regulated CD4+
T-cell responses to antigenic peptide and CD8+ responses against
the growth of B16 and EL-4 tumors, the latter event accompanied
by the increased infiltration and functionality of CD8+ TILs. Our
findings identify a novel TCR-associated negative regulator of
T-cell activation that has therapeutic potential in cancer
immunotherapy.
Peptides corresponding to Rasal1 were detected using tandem
affinity purification TCR zeta tandem affinity purification in
conjunction with mass spectrometry. This two-step TAP
approach minimizes nonspecific contaminating material, and has
been used successfully to purify other complexes with a high level
of purity48,49. To our knowledge, this is the first study to use the
TAP assay to identify new proteins associated with the TCR
complex. Aside from the expected TCR and CD3 subunits, Rasal1
was detected in multiple experiments (n= 3). This finding
underscores the effectiveness of the TAP approach in the iden-
tification of protein–protein interactions. Rasal1 was found to be
expressed weakly in resting T cells, and instead, is induced as a
consequence of the activation of CD4 and CD8+ T cells. It may,
therefore, play its main inhibitory role after the initial activation
of T cells. This inducible expression is reminiscent of IRs such as
CTLA-4 and PD-1 which are also expressed as a consequence of
T-cell activation2.
We further showed that Rasal1 is unusual in having the
potential to inhibit T-cell activation via at least two mechanisms.
First, we showed that Rasal1 binds to the kinase domain of ZAP-
70, and not other key regions of ZAP-70 such as the SH2 domains
or the regulatory SH2 intervening region. The binding to ZAP-70
explains why Rasal1 is co-precipitated with the TCR since ZAP-
70 binds to the CD3 and zeta chains of the complex7,9. PLA
analysis clearly showed that the interface of Rasal1 and ZAP-70
depends on ligation of the TCR complex. However, we cannot
exclude that Rasal1 may also bind to free ZAP-70, independent of
its binding to the TCR complex. Importantly, Rasal1 binding to
the ZAP-70 kinase domain inhibited its kinase activity as shown
by the reduced autophosphorylation and the phosphorylation of
the downstream substrate LAT. To our knowledge, this study is
the first reported identification of a GAP protein that binds the
ZAP-70 kinase domain to inhibit its catalytic activity. In this
context, it is interesting that some mutations in the catalytic
domain of ZAP-70 have been implicated in a blockade of thymic
differentiation and in autoimmunity10,60. Whether the level of
Rasal1 inhibition of ZAP-70 is sufficient to elicit effects on thymic
differentiation is unclear; however, it may help protect against
excess inflammation or autoimmunity and influence T-cell
responses to antigens of varying affinities. In this vein, we
noted that Rasal1 preferentially inhibits responses to higher
concentrations of anti-CD3. Rasal1 may act, therefore, to control
overstimulation and inflammation due to high strength TCR
signals61.
The second mode of inhibition involved the intrinsic GAP
activity of Rasal1 and its inhibition of the p21ras-ERK pathway.
We found that the transfection and expression of Rasal1 abro-
gated the phospho-activation of Raf1 (MEK3K), MEK1, and ERK,
but not p38, in response to TCR ligation. There are, therefore, two
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pathways by which Rasal1 negatively influences T-cell activation
underscoring its potential importance. The degree to which the
inhibition of ZAP-70 versus p21ras regulate T-cell activation and
effector functions remain for future studies. Rasal1 is a particu-
larly exciting TCR-associated upstream candidate for the anergy
induction in transplantation and autoimmunity, given its defined
role of the p21ras-ERK pathway in T-cell unresponsiveness32. It
also should be noted that despite our focus on p21ras, Rasal1 has
also been reported to have GAP activity toward the Ras-related
small GTPase, Rap40. Ras and Rap have somewhat different
functions. While Ras regulates proliferation, transcription, and
cell survival, Rap has been mostly implicated in adhesion and
cell–cell interactions. We previously showed that an adaptor
SKAP1 couples the TCR to the formation of a complex between
Rap1 and its ligand RapL for T-cell adhesion17,18. It is an intri-
guing possibility that Rasal1 binding to ZAP-70 of the TCR might
also negatively influence Rap1 activity in its control of T-cell
adhesion and motility. In this manner, the GAP protein may have
more than two roles in the regulation of T-cell immunology.
The GAP activity of Rasal1 differs from the mode of action of
other established negative regulators, such as the SHP-1/2 phos-
phatases and the E3 ubiquitin ligases. SHP-1/2 dephosphorylate
substrates62, and E3 ligases such as Cbl-b, Itch and Grail regulate
the ubiquitin pathway25. Perhaps the most similar mediator is the
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CAPRI (Ca2+ promoted Ras inactivator), which is also a Ca2+-
dependent GAP that switches off the Ras-MAPK pathway
following stimuli that elevate intracellular Ca2+ 40. Another less
direct pathway involves Cish, a suppressor of cytokine signaling
(SOCS), which inhibits PLCγ1 and Ras-ERK signaling63. Cish is
part of a multimolecular E3 ubiquitin ligase complex with an SH2
domain is essential for PLCγ1 regulation in TCR-stimulated
CD8+ T cells64. While Cish is primarily cytoplasmic and does not
cluster at the plasma membrane upon stimulation, Rasal1 has C2
domains to bind phospholipids in membranes, and which we
showed, translocates to membranes upon TCR ligation.
Lastly, we showed that the adoptive cell transfer of T cells
expressing Rasal1 siRNA limited the growth of two different
tumor types in mice. B16 tumor cells were injected intravenously
into mice and pulmonary metastasis assessed, while EL-4 cells
were injected subcutaneously and monitored for solid tumor
growth. The reduction in tumor growth was accompanied by a
marked increase in CD8+ TILs. In the case of B16 tumors, there
was a threefold increase in the presence of OT-1 CD8+ T cells in
tumors from mice injected with Rasal1 KD T cells. Further, these
cells showed an increase in the expression of GZMB and IFNγ1,
the effectors of CD8+ CTL killing of tumor targets65. In the case
of EL4 tumors, there was also a significant increase in the
numbers of OT-1 Rasal1 KD TILs relative to OT-1 scrambled KD
TILs, as well as an increase in TILs expressing CD25 and CD69.
In both tumor models, the level of CD62L expression was unaf-
fected suggesting that the TCR-Rasal1 pathway does not play a
role in the balance between memory vs effector T cells. Instead, it
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Fig. 8 Rasal1 KD T cells show reduced EL-4 tumor size concurrent with an increase in the presence of activated CD8+ TILs. a Upper panel: schematic of
EL4 solid tumor experiment. Lower panel: quantification of tumor size in mice receiving OT-1 cells expressing control scrambled siRNA or Rasal1 KD siRNA
T cells (n= 4 per group, lower panel). Upper inset panel shows representative images of some EL4 tumors from each group (scale bar, 5 mm). b Histogram
showing an increase in the percentage of CD8+ TILs in mice injected with CD8+ Rasal1 KD relative to scrambled siRNA T cells (left panel). No increase
was seen in the spleens of these mice (right panel). c Histograms showing an increase in the expression of CD25 and CD69 on CD8+ TILs from mice
injected with control scrambled siRNA or with Rasal1 KD siRNA T cells. d Histograms showing the MFI values for CD44 expression (left panel) and the
percentage of CD62L-positive CD8 TILs (right panel) from mice injected with scrambled siRNA or Rasal1 KD siRNA T cells
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may promote T cell entry into tumors and help arm CD8+
T cells for more effective tumor killing. We reported similar
effects mediated by the GSK-3 pathway in T cells57,58. Overall,
our findings identify a novel TCR-associated protein that nega-
tively regulates T-cell activation and antitumor immunity. Rasal1
inhibition could improve adoptive immunotherapies using tumor
antigen specific T cells66. siRNAs, CRISPR-Cas9, or SMIs of the
Rasal1 pathway could be used in ACT of T cells that express
tumor-specific T-cell receptors (TCRs) or chimeric antigen
receptors (CARs). Rasal1 and its binding to ZAP-70 and regula-
tion of the p21ras pathway may serve as a target for the devel-
opment of novel immunoregulatory drugs.
Methods
Cells, reagents, and antibodies. The 3A9 mouse T-cell hybridoma was obtained
from ATCC CRL-3293 (Manassas, Virginia, USA). AP-MS buffers, cell lysis buffer
(20mM Tris-HCl, pH 7.4, 1 × protease inhibitor mixture (Roche Applied Science),
50 mM NaCl, 1% (v/v) NP-40, 1% n-dodecyl β-D-maltoside (Calbiochem) or 1%
digitonin (Calbiochem), 1 mM sodium fluoride, 1 mM PMSF (Sigma), 1 mM beta-
glycerophosphate (Calbiochem)); wash buffer 1 (10mM Tris, pH 7.4, 50mm NaCl,
0.1% (v/v) NP-40, 0.1% n-dodecyl β-D-maltoside, 0.1 mM imidazole (Sigma)); wash
buffer 2 (10mM Tris, pH 7.4, 50mM NaCl, 0.1% (v/v) NP-40, 0.1% n-dodecyl β-D-
maltoside); elution buffer 1 (10mm Tris, pH 7.4, 50mM NaCl, 0.1% (v/v) NP-40,
0.1% n-dodecyl β-D-maltoside 1 × protease inhibitor mixture, 0.1 mg/ml of PMSF,
1–10 mM Imidazole (Sigma) gradient); elution buffer 2 (10 mm Tris, pH 7.4, 50
mm NaCl, 0.1% (v/v) NP-40, 0.1% n-dodecyl β-D-maltoside 1 × protease inhibitor
mixture, 0.1 mg/ml of PMSF, 2.5 mM D-desthiobiotin (IBA technology)). Rasal1
cDNA clones (Source Bioscience, Cambridge) were amplified and inserted into
Srα-vector with Flag- or HA-tag at the N-terminus of protein. pNFAT3-Luc
plasmid (contains three tandem repeats of the NFAT/AP1-binding site at ∼1287 bp
of the murine IL-2 promoter). Antibodies include anti-ERK1/2 (Cell Signaling, Cat.
# 9101 S), anti-zeta chain (Bio-rad Cat.# VMA00220 and BD Pharmingen, Cat. #
554241), anti-Rasal1 (Novus Biologicals Cat # NBP1-32776), anti-ZAP 70 (Cell
Signaling Cat#3165), rabbit anti-β-actin (Sigma, Cat.#A2228), 2C11 (BioxCell Cat.
#BE0001-1), OKT3 (BioxCell Cat.#BE0001-2), p38 (Cell Signaling Cat.#9212), anti-
Flag tag (Sigma Cat.# F1804), and anti-HA tag (ThermoFischer Cat.#26183). All
antibodies were used at 1:1000, except anti-β-actin (1:2000) for western blotting.
For flow cytometry antibodies were used at 1:100 dilutions.
Mice and T-cell enrichment. C57BL/6, DO11.10, BALB/c, OT-I, and Rag2−/−
mice were housed at the Central Biological Services (Cambridge University).
Animal studies were conducted in a gender and age-matched manner for all
experiments. Both male and female mice were used, and were 6–8 weeks of age at
the time of experiments. T cells were enriched from splenocytes, and LNs using a
negative selection column kit (R&D Systems) or MACS microbeads magnetic beads
(Miltenyi Biotech). Purity of isolated T cells was >90%.
TAP for MS. TCR-null zeta−/− 3A9 cells were reconstituted with HIS-STREP-II-
tagged Zeta to reintroduce surface TCR expression (Supplementary Fig. 1). Stable
clones were assessed for optimal surface and intracellular TCR abundance in
comparison with WT–control cells. A two-step sequential chromatography
approach was used to capture TCR and associated protein upon CD3 stimulation
under native non-denaturing conditions. Briefly, clarified lysates were loaded on
Pro-Bond Ni2+-NTA column (Invitrogen) followed by a second purification step,
Strep-Tactin sepharose column (IBA Lifesciences). Strep-II-tag protein fractions
were gravity eluted with D-desthiobiotin (IBA Lifesciences). Purity was assessed by
SDS gel and silver staining. TCR complex was enriched by concentration on a 100
kDa cutoff membrane (Amicon). For MS, gel fragments were destained in ddH2O
and 20mM NH4HCO3, reduced with 2 mM DTT, and alkylated with 10 mM
iodoacetamide prior to overnight digestion with 2 μg of sequencing grade trypsin
(Promega). ESI–MS was carried out with a 6130 Quadrupole spectrometer, and MS
acquisition carried out in positive ion mode, total protein masses were calculated
by deconvolution within the MS Chemstation software (Agilent Technologies). The
raw MS data files were searched against the UniprotKB Mus musculus database
using the Mascot search algorithm (version 2.2.07, Matrix Science, London, UK).
Significance threshold was set to p > 0.05 and ion score cutoff was set to 0. Protein
abundance was estimated by calculating emPAI scores. Proteins identified by at
least two unique peptides with an ion score of >30 were considered to be present,
which represented a 5% random match probability.
Flow cytometry, ex vivo stimulation, RT-PCR, and cellular fractionation. For
flow cytometry, surface and intracellular staining cells were processed as described
previously67. For ex vivo stimulation, TILs or splenocytes were stimulated with
PMA/Ionomycin for 6 h at 37° with Golgi Plug (BD). Real-time PCR was per-
formed using commercially available Taqman probe sets (Invitrogen) on ABI
PRISM 7000 SDS (Applied Biosystems, USA) instrument as per the manufacturer’s
instructions. RNA levels were normalized to endogenous housekeeping 18s rRNA
levels and plotted as a fold increase from resting cells. The results were analyzed
using SDS 1.2 software (Applied Biosystems, USA). Cytosolic and membrane
fractions were isolated from primary T cells, as described previously18.
Transfections, antigen presentation, transcription, and proliferation assays.
Primary T cells were transfected by microporation using Amaxa Nucleofector Kit
(Lonza) as per the instructions supplied with modification: cells were kept on ice
for 10 mins ice and in Amaxa solution A plus B (4.5:1) plus plasmid(s) for 1 min
prior to transfection. Antigen presentation and live cell imaging were done using
naive DO11.10T cells cultured at a density of 2 × 105/200 μl cells plus mitomycin-
C-treated autologous APCs pulsed with ovalbumin (OVA323-39) peptide. In vitro
proliferation was also assessed by directly pulsing with 1 μCi of [3 H] thymidine
during last 8 h of incubation. For transcription assay, luciferase reporter containing
NFAT-AP1 binding sites was co-transfected with control Renilla plasmid pRL-TK
(Promega) or Flag-Rasal1 for 24 h. Cell were anti-CD3 stimulated for additional 6 h
and activity measured using dual luciferase assay kit (Promega) on a MicroLumat
Luminator (Berthold).
Endogenous Rasal1 KD. We used MISSION esiRNA (Sigma, Cat. No.
EMU036111-50UG) that are endo-ribonuclease prepared siRNA. MISSION
esiRNA are a heterogeneous mixture of siRNAs that all target the same mRNA
sequence, in part based on previous shRNA knockdown studies68. These multiple
silencing triggers lead to highly specific and effective gene silencing. esiRNA cDNA
Rasal1 target sequence is given below:
GACGTGTCTGGAAGCAGTGACCCCTATTGTCTGGTGAAAGTGGATGA
CCAAGTGGTGGCCAGGACAGCAACCATCTGGAGGAGCCTGAGCCCCTT
TTGGGGGGAGGAGTACACCGTTCACCTTCCATTGGACTTCCACCACCTG
GCCTTCTACGTGCTGGATGAGGACACCGTTGGACACGATGACATCATTG
GGAAGATCTCATTGAGCAAAGAGGCGATCACAGCCGACCCTCGAGGGAT
CGACAGCTGGATCAACCTGAGCCGAGTGGATCCAGACGCTGAAGTACAG
GGTGAGGTCTGCCTGGATGTGAAGCTATTGGAGGATGCTCGGGGCCG
CTGCCTCCGCTGCCACGTGAGACAGGCCAGGGACCTGGCCCCCCGGGA
CATCTCTGGCACATCGGACCCATTTGCCCGTGTGTTCTGGGGCAACCAT
AGTTTGGAAACTTCGACCATCAAGAAGACCCGCTTTCCACACTGGGATG
AGGTGTTG.
esiRNA scrambled cDNA target sequence. GTGAGCAAGGGCGAGGAGCTG
TTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAAC
GGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTA
CGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTG
CCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCA
GCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCC
ATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGAC
GGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTG
GTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAAC
ATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATA
TCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCG
CCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCA
GAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTA
CCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCG
ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACT
CTCGGCATGGACGAGCTGTA.
Phospho-ERK and p38 assay. Primary T cells transfected with control or Flag-
tagged Rasal1 were stimulated with anti-CD3 antibodies 2C11 (2–5 μg/ml) plus
cross-linking RαM (1.25 μg/ml). Reaction was stopped with cold Stop Solution
(PBS containing 1 mM Sodium Vanadate plus 1 mM EDTA). PMA (50 ng) and
ionomycin (1 μg/ml) was used as control. Cells were fixed and permeabilized with
methanol, and phospho-staining performed.
In situ proximity ligation assay. Proximity ligation assay was performed using
Duolink in situ PLA reagents50 on Jurkat cells. Cells on slides were blocked with
Duolink Blocking stock followed by the application of two PLA probes in 1 ×
antibody diluent. The slides were washed in a wash buffer (1 × TBS-T) for 5 min
twice and processed for hybridization using Duolink Hybridization stock 1:5 in
high purity water and followed by incubation for 15 min at 37 °C. Duolink Ligation
was performed with ligase, and the slides were incubated in a pre-heated humidity
chamber for 15 min at 37 °C. Amplification was then achieved using Duolink
Amplification stock containing the polymerase, and the slides were incubated again
in a pre-heated humidity chamber for 90 min at 37 °C. DNA was stained with
DAPI. One individual dot represents the close proximity of two interacting pro-
teins within the cells.
Tumor experiments. The research was regulated under the Animals (Scientific
Procedures) Act 1986 Amendment Regulations 2012 following ethical review by
the University of Cambridge Animal Welfare and Ethical Review Body (AWERB)
Home Office UK PPL No. 70/7544. We complied with all ethical regulations for the
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work with mice. For lung tumors, B16F10 melanoma cells were pulsed with
OVA257-264 overnight, trypsinized, and resuspended in PBS, and then 2 × 105 cells
(in 0.2 mL) were injected via the lateral tail vein on day 0. Mice were injected with
OT-I cells or PBS alone on day 1. Mice were killed day 14, and tissues were isolated.
Some lungs were also immersed in Bouin solution to distinguish white tumor
colonies from yellowish lung parenchyma. Surface metastatic foci in lung left lobes
were counted manually. For establishing EL-4 lymphoma tumors, at day 0, 105 EL-
4 cells were injected intradermally into the right flanks of mice. Five days after
tumor implantation, control esiRNA OT-I or Rasal1 esiRNA transfected OT-I cells
were given intravenously. Four mice per group bearing EL4 tumors were kiled
when tumor from control mouse (OT-I cells alone) reached limit (12 mm). Tumors
were sampled for CD8 TILs infiltration and activation markers.
Western blotting. Cells were transfected and 24 h lysed with RIPA buffer (50 mM
Tris-HCL pH 8,0, 150 mM NaCl, 1% Triton X-100, 0,5% Na-desoxycholate, 01.%
SDS, 1 mM Na3VO4, 1 mM PMSF, 1 mM DTT, and protease inhibitor complete
(Roche). Polyvinylidene difluoride (PVDF) membranes were used for western
blotting applications. Blocking of membranes was performed with TBST, including
2% BSA. The membrane was incubated with the first antibody (1:1000) for 1 h or
overnight followed by HRP-conjugated secondary antibodies (1:5000) (GE
Healthcare). The ECL western blotting substrate was used for detection.
In vitro kinase assays. In vitro kinase assays were performed using 10× PK buffer
(New England Biolabs) supplemented with 0.05 mM ATP and 1 μCi of (γ-32)ATP
(3000 Ci/mmol; Amersham Pharmacia) for 30 min at 37 °C in the presence of
recombinant human active ZAP-70 Kinase (ProQuinase), as previously
described6,7. Bacterially expressed purified GST proteins or Flag-expressed proteins
from 293T cells served as substrates. Flag-LAT used in the kinase assays was
immunoprecipitated from 293T cells. Samples were resolved by SDS/PAGE and
subjected to autoradiography or western blotting.
Immunoprecipitation. Cell lysates were incubated with Protein-G sepharose beads
(GE Healthcare) and the specific antibody overnight at 4 °C. Immunoprecipitates
were washed three times with ice-cold buffer (20 mM Tris-HCl ph 8.2, 150 mM
NaCl, 1% (v/v) TritonX-100 and analyzed by western blotting17,69,70.
Statistical analysis. All statistical analysis was performed using Prism 6 software
(GraphPad Software). An ANOVA test was used to test the significance of the
changes between groups.
Data availability
The authors declare that the data supporting the findings of this study are available
within the article and its supplementary information files. Any further information on
the proteomics data is available from author on request.
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